ArticleFrontiers in immunology2023

Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy.

Hweixian Leong Penny et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.